Antibodies to citrullinated proteins in arthritis: Pathology and promise

Current Opinion in Rheumatology

Volumn 20, Issue 3, 2008, Pages 300-305

  Klareskog, Lars ^a   Widhe, Mona ^a   Hermansson, Monika ^a   Rönnelid, Johan ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antibodies to citrullinated protein antigens; Environmental factors triggering rheumatoid arthritis; Genetics of rheumatoid arthritis; Subdivisions of rheumatoid arthritis by pathogenetic principles

Indexed keywords

ANTIBODY; ANTIGEN; BIOLOGICAL MARKER; CITRULLINATED PROTEIN; CITRULLINATED PROTEIN ANTIBODY; CITRULLINE; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTIBODY TITER; DIAGNOSTIC VALUE; DISEASE MARKER; EARLY DIAGNOSIS; GENETIC RISK; HUMAN; HUMORAL IMMUNITY; IMMUNOPATHOGENESIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; HUMANS; INFLAMMATION; PEPTIDES, CYCLIC;

EID: 41549169663     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3282fbd22a     Document Type: Review

References (65)

1. Chavanas S, Mechin MC, Takahara H, et al. Comparative analysis of the mouse and human peptidylarginine deiminase gene clusters reveals highly conserved noncoding segments and a new human gene, PADI6. Gene 2004; 330:19-27.
2. Vossenaar ER, Zendman AJ, van Venrooij WJ, Pruijn GJ. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays 2003; 25:1106-1118.
3. Gyorgy B, Toth E, Tarcsa E, et al. Citrullination: a posttranslational modification in health and disease. Int J Biochem Cell Biol 2006; 38:1662-1677.
4. Tarcsa E, Marekov LN, Mei G, et al. Protein unfolding by peptidylarginine deiminase: substrate specificity and structural relationships of the natural substrates trichohyalin and filaggrin. J Biol Chem 1996; 271:30709-30716.
5. Asaga H, Yamada M, Senshu T. Selective deimination of vimentin in calcium ionophore-induced apoptosis of mouse peritoneal macrophages. Biochem Biophys Res Commun 1998; 243:641-646.
6. Mizoguchi M, Manabe M, Kawamura Y, et al. Deimination of 70-kDa nuclear protein during epidermal apoptotic events in vitro. J Histochem Cytochem 1998; 46:1303-1309.
7. Senshu T, Kan S, Ogawa H, et al. Preferential deimination of keratin K1 and filaggrin during the terminal differentiation of human epidermis. Biochem Biophys Res Commun 1996; 225:712-719.
8. Nogueira L, Sebbag M, Vincent C, et al. Performance of two ELISAs for antifilaggrin autoantibodies, using either affinity purified or deiminated recombinant human filaggrin, in the diagnosis of rheumatoid arthritis. Ann Rheum Dis 2001; 60:882-887.
9. Schellekens GA, de Jong BA, van den Hoogen FH, et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998; 101:273-281.
10. Pritzker LB, Joshi S, Gowan JJ, et al. Deimination of myelin basic protein. 1. Effect of deimination of arginyl residues of myelin basic protein on its structure and susceptibility to digestion by cathepsin D. Biochemistry 2000; 39:5374-5381.
11. Nicholas AP, Whitaker JN. Preparation of a monoclonal antibody to citrullinated epitopes: its characterization and some applications to immunohistochemistry in human brain. Glia 2002; 37:328-336.
12. Bongartz T, Cantaert T, Atkins SR, et al. Citrullination in extra-articular manifestations of rheumatoid arthritis. Rheumatology (Oxford) 2007; 46: 70-75. This article describes patterns of citrullination that may be of importance for triggering of anticitrullin immunity in RA.
13. Makrygiannakis D, af Klint E, Lundberg IE, et al. Citrullination is an inflammation-dependent process. Ann Rheum Dis 2006; 65:1219-1222.
14. Vossenaar ER, Smeets TJ, Kraan MC, et al. The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum 2004; 50:3485-3494.
15. Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006; 54:38-46.
16. Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol 2001; 166:4177-4184.
17. Vossenaar ER, Despres N, Lapointe E, et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 2004; 6:R142-R150.
18. Bang H, Egerer K, Gauliard A, et al. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 2007; 56:2503-2511. This paper extends the observations of the diagnostic value of ACPA to vimentin, which as a very interesting protein, being a potential target for autoimmity in RA.
19. Kinloch A, Tatzer V, Wait R, et al. Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther 2005; 7:R1421-R1429.
20. Young BJ, Mallya RK, Leslie RD, et al. Antikeratin antibodies in rheumatoid arthritis. Br Med J 1979; 2:97-99.
21. Sebbag M, Simon M, Vincent C, et al. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 1995; 95:2672-2679.
22. Schellekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43:155-163.
23. Vossenaar ER, van Venrooij WJ. Anti-CCP antibodies, a highly specific marker for (early) rheumatoid arthritis. Clin Appl Immunol Rev 2004; 4:239-262.
24. Bogliolo L, Alpini C, Caporali R, et al. Antibodies to cyclic citrullinated peptides in psoriatic arthritis. J Rheumatol 2005; 32:511-515.
25. Korendowych E, Owen P, Ravindran J, et al. The clinical and genetic associations of anticyclic citrullinated peptide antibodies in psoriatic arthritis. Rheumatology (Oxford) 2005; 44:1056-1060.
26. Vander Cruyssen B, Hoffman IE, Zmierczak H, et al. Anticitrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis 2005; 64:1145-1149.
27. Alenius GM, Berglin E, Rantapää Dahlqvist S. Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation. Ann Rheum Dis 2006; 65:398-400.
28. Low JM, Chauhan AK, Kietz DA, et al. Determination of anticyclic citrullinated peptide antibodies in the sera of patients with juvenile idiopathic arthritis. J Rheumatol 2004; 31:1829-1833.
29. Kasapcopur O, Altun S, Aslan M, et al. Diagnostic accuracy of anticyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 2004; 63:1687-1689.
30. Ferucci ED, Majka DS, Parrish LA, et al. Antibodies against cyclic citrullinated peptide are associated with HLA-DR4 in simplex and multiplex polyarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 2005; 52:239-246.
31. Kwok JS, Hui KH, Lee TL, et al. Anticyclic citrullinated peptide: diagnostic and prognostic values in juvenile idiopathic arthritis and rheumatoid arthritis in a Chinese population. Scand J Rheumatol 2005; 34:359-366.
32. Martinez JB, Valero JS, Bautista AJ, et al. Erosive arthropathy: clinical variance in lupus erythematosus and association with anti-CCP case series and review of the literature. Clin Exp Rheumatol 2007; 25:47-53.
33. Takasaki Y, Yamanaka K, Takasaki C, et al. Anticyclic citrullinated peptide antibodies in patients with mixed connective tissue disease. Mod Rheumatol 2004; 14:367-375.
34. Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: diagnostic accuracy of anticyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007; 146:797-808.
35. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anticyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2006; 65:845-851.
36. Meyer O, Labarre C, Dougados M, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003; 62:120-126.
37. Vencovsky J, Machacek S, Sedova L, et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003; 62:427-430.
38. Forslind K, Ahlmen M, Eberhardt K, et al. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 2004; 63:1090-1095.
39. Kroot EJ, de Jong BA, van Leeuwen MA, et al. The prognostic value of anticyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000; 43:1831-1835.
40. Rönnelid J, Wick MC, Lampa J, et al. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 2005; 64:1744-1749.
41. Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 2004; 63:1085-1089.
42. Kurki P, Aho K, Palosuo T, Heliovaara M. Immunopathology of rheumatoid arthritis: antikeratin antibodies precede the clinical disease. Arthritis Rheum 1992; 35:914-917.
43. Aho K, Palosuo T, Heliovaara M, et al. Antifilaggrin antibodies within 'normal' range predict rheumatoid arthritis in a linear fashion. J Rheumatol 2000; 27:2743-2746.
44. Rantapää-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48:2741-2749.
45. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004; 50:380-386.
46. Lundberg K, Nijenhuis S, Vossenaar ER, et al. Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res Ther 2005; 7:R458-R467.
47. Kuhn KA, Kulik L, Tomooka B, et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 2006; 116:961-973.
48. Huizinga TW, Amos CI, van der Helm-van Mil AH, et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum 2005; 52:3433-3438.
49. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, et al. The HLADRB1 shared epitope alleles are primarily a risk factor for anticyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum 2006; 54:1117-1121.
50. Johansson M, Arlestig L, Hallmans G, Rantapää-Dahlqvist S. PTPN22 polymorphism and anticyclic citrullinated peptide antibodies in combination strongly predicts future onset of rheumatoid arthritis and has a specificity of 100% for the disease. Arthritis Res Ther 2006; 8:R19.
51. Källberg H, Padyukov L, Plenge RM, et al. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 2007; 80:867-875.
52. Kokkonen H, Johansson M, Innala L, et al. The PTPN22 1858C/T polymorphism is associated with anticyclic citrullinated peptide antibodypositive early rheumatoid arthritis in northern Sweden. Arthritis Res Ther 2007; 9:R56.
53. Plenge RM, Seielstad M, Padyukov L, et al. TRAF1-C5 as a risk locus for rheumatoid arthritis: a genomewide study. N Engl J Med 2007; 357:1199-1209.
54. Sigurdsson S, Padyukov L, Kurreeman FA, et al. Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis. Arthritis Rheum 2007; 56:2202-2210.
55. Lorentzen JC, Flornes L, Eklöw C, et al. Association of arthritis with a gene complex encoding C-type lectin-like receptors. Arthritis Rheum 2007; 56:2620-2632.
56. Pedersen M, Jacobsen S, Garred P, et al. Strong combined gene-environment effects in anticyclic citrullinated peptide-positive rheumatoid arthritis: a nationwide case-control study in Denmark. Arthritis Rheum 2007; 56:1446-1453.
57. Hill JA, Southwood S, Sette A, et al. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003; 171:538-541.
58. Katz J, Goultschin J, Benoliel R, Brautbar C. Human leukocyte antigen (HLA) DR4: positive association with rapidly progressing periodontitis. J Periodontol 1987; 58:607-610.
59. Marotte H, Farge P, Gaudin P, et al. The association between periodontal disease and joint destruction in rheumatoid arthritis extends the link between the HLA-DR shared epitope and severity of bone destruction. Ann Rheum Dis 2006; 65:905-909.
60. Pratesi F, Tommasi C, Anzilotti C, et al. Deiminated Epstein-Barr virus nuclear antigen 1 is a target of anticitrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum 2006; 54:733-741.
61. Plenge RM, Padyukov L, Remmers EF, et al. Replication of putative candidategene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet 2005; 77:1044-1060.
62. Wesoly J, van der Helm-van Mil AH, Toes RE, et al. Association of the PTPN22 C1858T single-nucleotide polymorphism with rheumatoid arthritis phenotypes in an inception cohort. Arthritis Rheum 2005; 52:2948-2950.
63. Remmers EF, Plenge RM, Lee AT, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007; 357:977-986.
64. Klareskog L, Forsum U, Scheynius A, et al. Evidence in support of a self-perpetuating HLA-DR-dependent delayed-type cell reaction in rheumatoid arthritis. Proc Natl Acad Sci U S A 1982; 79:3632-3636.
65. van Dongen H, van Aken J, Lard LR, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007; 56:1424-1432.